Overview of Laboratory Testing and Clinical Presentations of Complement Deficiencies and Dysregulation

被引:31
作者
Frazer-Abel, A. [1 ]
Sepiashvili, L. [2 ]
Mbughuni, M. M. [2 ]
Willrich, M. A. V. [2 ]
机构
[1] Natl Jewish Hlth, Denver, CO USA
[2] Mayo Clin, Rochester, MN USA
来源
ADVANCES IN CLINICAL CHEMISTRY, VOL 77 | 2016年 / 77卷
关键词
HEMOLYTIC-UREMIC SYNDROME; C1 INHIBITOR DEFICIENCY; FACTOR-H-AUTOANTIBODIES; HEREDITARY ANGIONEUROTIC-EDEMA; SYSTEMIC-LUPUS-ERYTHEMATOSUS; PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; ACQUIRED C1-INHIBITOR DEFICIENCY; PRECEDES MULTIPLE-MYELOMA; PRIMARY SJOGRENS-SYNDROME;
D O I
10.1016/bs.acc.2016.06.001
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Historically, complement disorders have been attributed to immunodeficiency associated with severe or frequent infection. More recently, however, complement has been recognized for its role in inflammation, autoimmune disorders, and vision loss. This paradigm shift requires a fundamental change in how complement testing is performed and interpreted. Here, we provide an overview of the complement pathways and summarize recent literature related to hereditary and acquired angioedema, infectious diseases, autoimmunity, and age-related macular degeneration. The impact of complement dysregulation in atypical hemolytic uremic syndrome, paroxysmal nocturnal hemoglobinuria, and C3 glomerulopathies is also described. The advent of therapeutics such as eculizumab and other complement inhibitors has driven the need to more fully understand complement to facilitate diagnosis and monitoring. In this report, we review analytical methods and discuss challenges for the clinical laboratory in measuring this complex biochemical system.
引用
收藏
页码:1 / 75
页数:75
相关论文
共 313 条
[1]   Open-label, multicenter study of self-administered icatibant for attacks of hereditary angioedema [J].
Aberer, W. ;
Maurer, M. ;
Reshef, A. ;
Longhurst, H. ;
Kivity, S. ;
Bygum, A. ;
Caballero, T. ;
Bloom, B. ;
Nair, N. ;
Malbran, A. .
ALLERGY, 2014, 69 (03) :305-314
[2]   Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease) [J].
Abrera-Abeleda, M. A. ;
Nishimura, C. ;
Smith, J. L. H. ;
Sethi, S. ;
McRae, J. L. ;
Murphy, B. F. ;
Silvestri, G. ;
Skerka, C. ;
Jozsi, M. ;
Zipfel, P. F. ;
Hageman, G. S. ;
Smith, R. J. H. .
JOURNAL OF MEDICAL GENETICS, 2006, 43 (07) :582-589
[3]   Allelic Variants of Complement Genes Associated with Dense Deposit Disease [J].
Abrera-Abeleda, Maria Asuncion ;
Nishimura, Carla ;
Frees, Kathy ;
Jones, Michael ;
Maga, Tara ;
Katz, Louis M. ;
Zhang, Yuzhou ;
Smith, Richard J. H. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2011, 22 (08) :1551-1559
[4]   HEREDITARY AND ACQUIRED C1-INHIBITOR DEFICIENCY - BIOLOGICAL AND CLINICAL CHARACTERISTICS IN 235 PATIENTS [J].
AGOSTONI, A ;
CICARDI, M .
MEDICINE, 1992, 71 (04) :206-215
[5]   Eculizumab for the treatment of two recurrences of atypical hemolytic uremic syndrome in a kidney allograft [J].
Alachkar, Nada ;
Bagnasco, Serena M. ;
Montgomery, Robert A. .
TRANSPLANT INTERNATIONAL, 2012, 25 (08) :e93-e95
[6]   Crystal Structure of C5b-6 Suggests Structural Basis for Priming Assembly of the Membrane Attack Complex [J].
Aleshin, Alexander E. ;
DiScipio, Richard G. ;
Stec, Boguslaw ;
Liddington, Robert C. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (23) :19642-19652
[7]  
Ali Ola S M, 2005, Egypt J Immunol, V12, P91
[8]   ACQUIRED C1 INHIBITOR (C1-INH) DEFICIENCY TYPE-II - REPLACEMENT THERAPY WITH C1-INH AND ANALYSIS OF PATIENTS C1-INH AND ANTI-C1-INH AUTOANTIBODIES [J].
ALSENZ, J ;
LAMBRIS, JD ;
BORK, K ;
LOOS, M .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 83 (06) :1794-1799
[9]   Perspective - A role for local inflammation in the formation of drusen in the aging eye [J].
Anderson, DH ;
Mullins, RF ;
Hageman, GS ;
Johnson, LV .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2002, 134 (03) :411-431
[10]  
Andreguetto B, 2015, MOL IMMUNOL, V67, P119